NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
Investment will support Odyssey’s portfolio of clinical and preclinical medicines designed to precisely treat the drivers of complex autoimmune diseases. Jeito will leverage its global network, expertise and strong value creation track record in immunology and...
Download our White Paper
We are pleased to share with you our White Paper, which offers a deep dive into the evolving biopharma landscape and highlights the key trends shaping its future.
Find all our press releases
Rafaèle Tordjman, Founder and CEO of Jeito, is awarded Chevalier of the Légion d’Honneur
Paris, France, 30 September 2020 – Jeito Capital (“Jeito”), a rapidly emerging independent...
Jeito Capital co-leads $110 Million Series A Financing in Neogene Therapeutics
Neogene becomes Jeito Capital’s first investment following the fund I launch in January 2020 Round...
Rafaèle Tordjman launches JEITO CAPITAL, a new private equity company dedicated to biotech-biopharmaceuticals
Paris, January 13, 2020 - Rafaèle Tordjman launches JEITO CAPITAL, a new French and independent...
Face to face
Meet Jeito
12-15
January
All day long
JPM Healthcare Conference 2026
Jeito will be present at the 44th JPM Healthcare Conference 2026, renowned as the largest and most influential healthcare investment symposium, attracting global industry leaders, Biotech companies, and members of the investment community, in San Francisco.